Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7.

Goupille O, Penglong T, Lefèvre C, Granger M, Kadri Z, Fucharoen S, Maouche-Chrétien L, Leboulch P, Chrétien S.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):1-5. doi: 10.1016/j.bbrc.2012.10.112. Epub 2012 Nov 5.

PMID:
23137537
2.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

4.

Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.

Gewirtz DA, Di X, Walker TD, Sawyer ST.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2232-8.

5.

Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia.

Jacobs-Helber SM, Roh KH, Bailey D, Dessypris EN, Ryan JJ, Chen J, Wickrema A, Barber DL, Dent P, Sawyer ST.

Blood. 2003 Jan 15;101(2):524-31. Epub 2002 Aug 29.

6.

Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.

Negre O, Fusil F, Henri A, Villette JM, Leboulch P, Beuzard Y, Payen E.

Exp Hematol. 2008 Apr;36(4):412-23. doi: 10.1016/j.exphem.2007.12.004. Epub 2008 Mar 4.

PMID:
18295963
7.
8.

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.

Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1.

9.
10.

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.

Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT.

Cancer Lett. 2017 May 28;394:76-87. doi: 10.1016/j.canlet.2017.02.021. Epub 2017 Feb 27.

PMID:
28254412
11.

Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells.

Prade-Houdellier N, Frébet E, Demur C, Gautier EF, Delhommeau F, Bennaceur-Griscelli AL, Gaudin C, Martinel V, Laurent G, Mansat-De Mas V, Beyne-Rauzy O.

Leukemia. 2007 Nov;21(11):2304-10. Epub 2007 Aug 23.

PMID:
17713555
12.

Erythropoietin activates the receptor in both Rauscher and Friend murine erythroleukemia cells.

Chern Y, Spangler R, Choi HS, Sytkowski AJ.

J Biol Chem. 1991 Feb 5;266(4):2009-12.

13.

Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.

Chrétien S, Varlet P, Verdier F, Gobert S, Cartron JP, Gisselbrecht S, Mayeux P, Lacombe C.

EMBO J. 1996 Aug 15;15(16):4174-81.

14.

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.

Stewart HJ, Horne GA, Bastow S, Chevassut TJ.

Cancer Med. 2013 Dec;2(6):826-35. doi: 10.1002/cam4.146. Epub 2013 Oct 31.

15.

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Lockwood WW, Zejnullahu K, Bradner JE, Varmus H.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19408-13. doi: 10.1073/pnas.1216363109. Epub 2012 Nov 5.

16.

BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.

Kamijo H, Sugaya M, Takahashi N, Oka T, Miyagaki T, Asano Y, Sato S.

Arch Dermatol Res. 2017 Aug;309(6):491-497. doi: 10.1007/s00403-017-1749-9. Epub 2017 Jun 7.

PMID:
28593508
17.

Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation.

Buck I, Morceau F, Cristofanon S, Heintz C, Chateauvieux S, Reuter S, Dicato M, Diederich M.

Biochem Pharmacol. 2008 Nov 15;76(10):1229-39. doi: 10.1016/j.bcp.2008.08.025. Epub 2008 Sep 2.

PMID:
18805401
18.

HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.

Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N.

Leukemia. 2008 Mar;22(3):578-84. Epub 2007 Dec 6.

PMID:
18059484
19.

STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line.

Iwatsuki K, Endo T, Misawa H, Yokouchi M, Matsumoto A, Ohtsubo M, Mori KJ, Yoshimura A.

J Biol Chem. 1997 Mar 28;272(13):8149-52.

20.

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, Zhang H.

Clin Cancer Res. 2015 Jan 1;21(1):113-22. doi: 10.1158/1078-0432.CCR-13-3346. Epub 2014 Jul 9.

Supplemental Content

Support Center